Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Expected to Announce Quarterly Sales of $4.23 Billion

Wall Street brokerages expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to report $4.23 billion in sales for the current quarter, Zacks reports. Eight analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The highest sales estimate is $4.35 billion and the lowest is $4.15 billion. Teva Pharmaceutical Industries reported sales of $4.53 billion in the same quarter last year, which would suggest a negative year over year growth rate of 6.6%. The business is scheduled to announce its next earnings report before the market opens on Thursday, November 7th.

On average, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $17.18 billion for the current year, with estimates ranging from $17.02 billion to $17.36 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $17.02 billion, with estimates ranging from $16.63 billion to $17.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The company had revenue of $4.34 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter last year, the company posted $0.78 earnings per share. The firm’s quarterly revenue was down 7.7% on a year-over-year basis.

Several research analysts have recently weighed in on the stock. Guggenheim assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They set a “neutral” rating on the stock. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Wells Fargo & Co dropped their price target on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a research note on Monday, September 30th. Credit Suisse Group reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, July 10th. Finally, Gabelli upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and a consensus target price of $11.17.

Hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Teva Pharmaceutical Industries by 7.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 327,489 shares of the company’s stock worth $2,253,000 after purchasing an additional 23,000 shares during the period. Wedbush Securities Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 32.6% during the 3rd quarter. Wedbush Securities Inc. now owns 42,347 shares of the company’s stock worth $291,000 after purchasing an additional 10,403 shares during the period. Envestnet Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $82,000. G&S Capital LLC boosted its stake in shares of Teva Pharmaceutical Industries by 49.9% during the 3rd quarter. G&S Capital LLC now owns 6,012 shares of the company’s stock worth $41,000 after purchasing an additional 2,000 shares during the period. Finally, Commerzbank Aktiengesellschaft FI boosted its stake in shares of Teva Pharmaceutical Industries by 49.4% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 8,682,389 shares of the company’s stock worth $59,735,000 after purchasing an additional 2,869,139 shares during the period. Hedge funds and other institutional investors own 57.78% of the company’s stock.

TEVA stock traded down $0.27 on Tuesday, hitting $7.50. The company had a trading volume of 19,799,744 shares, compared to its average volume of 17,383,628. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $23.97. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The stock’s 50-day simple moving average is $7.16 and its 200 day simple moving average is $9.59. The stock has a market cap of $8.48 billion, a price-to-earnings ratio of 2.68, a P/E/G ratio of 0.81 and a beta of 1.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.